Overview

Sitagliptin and Endothelial Dysfunction

Status:
Unknown status

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

Over the years, numbers of cardioprotective drugs have been evaluated to attenuate lethal ischemia-reperfusion (IR) injuries. There is little study whether sitagliptin protects against endothelial dysfunction induced by IR injury in humans.

Phase:

Phase 3

Details

Lead Sponsor:

Kyunghee University Medical Center

Treatments:

Sitagliptin Phosphate